Published in Scand J Gastroenterol Suppl on January 01, 1997
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut (2006) 9.03
Prevalence of Helicobacter pylori seropositivity among patients undergoing bariatric surgery: a preliminary study. World J Surg (2008) 2.22
Atrophic gastritis and Helicobacter pylori infection in outpatients referred for gastroscopy. Gut (2000) 1.02
Seroconversion and seroreversion in IgG antibodies to Helicobacter pylori: a serology based prospective cohort study. J Epidemiol Community Health (2000) 1.02
Helicobacter pylori infection and low serum pepsinogen I level as risk factors for gastric carcinoma. World J Gastroenterol (2005) 0.88
Long-term proton pump inhibitor use and gastrointestinal cancer. Curr Gastroenterol Rep (2008) 0.88
Diversity of Helicobacter pylori isolates in expression of antigens and induction of antibodies. World J Gastroenterol (2008) 0.85
Suppressed Gastric Mucosal TGF-beta1 Increases Susceptibility to H. pylori-Induced Gastric Inflammation and Ulceration: A Stupid Host Defense Response. Gut Liver (2010) 0.85
Assessing the risks and benefits of treating Helicobacter pylori infection. Therap Adv Gastroenterol (2009) 0.85
Human peripheral and gastric lymphocyte responses to Helicobacter pylori NapA and AphC differ in infected and uninfected individuals. Gut (2005) 0.84
Gastric juice acidity in upper gastrointestinal diseases. World J Gastroenterol (2010) 0.81
Does gastric atrophy exist in children? World J Gastroenterol (2006) 0.79
Regular arrangement of collecting venules: Does patient age affect its accuracy? World J Gastrointest Endosc (2011) 0.77
The Diagnostic Value of Gastrin-17 Detection in Atrophic Gastritis: A Meta-Analysis. Medicine (Baltimore) (2016) 0.75
Reciprocal impact of host factors and Helicobacter pylori genotypes on gastric diseases. World J Gastroenterol (2015) 0.75
Implications of anti-parietal cell antibodies and anti-Helicobacter pylori antibodies in histological gastritis and patient outcome. World J Gastroenterol (2005) 0.75
The efficacy of Jianpi Yiqi therapy for chronic atrophic gastritis: A systematic review and meta-analysis. PLoS One (2017) 0.75
Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst (1995) 6.07
Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol (1998) 5.77
Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: randomised clinical trial. The Netherlands Antireflux Surgery Study Group. Lancet (2000) 5.31
Molecular typing of methicillin-resistant Staphylococcus aureus on the basis of protein A gene polymorphism. Eur J Clin Microbiol Infect Dis (1996) 4.87
Variant esp gene as a marker of a distinct genetic lineage of vancomycin-resistant Enterococcus faecium spreading in hospitals. Lancet (2001) 4.52
Long-term sequelae of Helicobacter pylori gastritis. Lancet (1995) 4.26
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med (1996) 4.11
Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med (1994) 4.00
Randomised trial of glutamine-enriched enteral nutrition on infectious morbidity in patients with multiple trauma. Lancet (1998) 2.84
Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett's esophagus with early neoplasia: a prospective multicenter study. Endoscopy (2013) 2.76
Discrimination of epidemic and nonepidemic methicillin-resistant Staphylococcus aureus strains on the basis of protein A gene polymorphism. J Clin Microbiol (1994) 2.72
Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis (1995) 2.69
Identification of epidemic strains of Acinetobacter baumannii by integrase gene PCR. J Clin Microbiol (2001) 2.66
Clostridial toxin in faeces of healthy infants. Lancet (1978) 2.58
Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. FEMS Microbiol Lett (1996) 2.42
Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol (1999) 2.33
Stable amoxicillin resistance in Helicobacter pylori. Lancet (1998) 2.20
Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol (1997) 2.17
Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol (1995) 2.12
Detection of a nosocomial outbreak of salmonellosis may be delayed by application of a protocol for rejection of stool cultures. J Hosp Infect (2003) 2.04
Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in The Netherlands. J Clin Microbiol (1997) 2.02
Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease. FEMS Immunol Med Microbiol (1996) 1.97
Coccoid forms of Helicobacter pylori are the morphologic manifestation of cell death. Infect Immun (1997) 1.96
Seroconversion for Helicobacter pylori. Lancet (1993) 1.88
Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol (1996) 1.86
Comparison of amplified ribosomal DNA restriction analysis, random amplified polymorphic DNA analysis, and amplified fragment length polymorphism fingerprinting for identification of Acinetobacter genomic species and typing of Acinetobacter baumannii. J Clin Microbiol (1998) 1.85
Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology (1996) 1.83
Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet (1987) 1.83
Analysis of the lympho-plasmacytic infiltrate in Crohn's disease with special reference to identification of lymphocyte-subpopulations. Gut (1976) 1.83
Learning to perform endoscopic resection of esophageal neoplasia is associated with significant complications even within a structured training program. Endoscopy (2011) 1.82
Typing of Helicobacter pylori with monoclonal antibodies against Lewis antigens in lipopolysaccharide. J Clin Microbiol (1996) 1.78
Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol (1995) 1.74
Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother (1999) 1.73
Helicobacter pylori: a true carcinogen? Eur J Gastroenterol Hepatol (1998) 1.72
Impaired anamnestic cellular immune response in patients with Crohn's disease. Gut (1975) 1.65
Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol (2000) 1.62
Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol (1997) 1.62
Characterization of the epitope specificity of murine monoclonal antibodies directed against lipid A. Infect Immun (1992) 1.61
Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther (1998) 1.61
Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals. Eur J Clin Microbiol Infect Dis (1996) 1.60
Phase variation in Helicobacter pylori lipopolysaccharide. Infect Immun (1998) 1.60
Nickel-responsive induction of urease expression in Helicobacter pylori is mediated at the transcriptional level. Infect Immun (2001) 1.59
comH, a novel gene essential for natural transformation of Helicobacter pylori. J Bacteriol (2000) 1.57
Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother (1998) 1.56
Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by comparative genomic hybridisation. J Clin Pathol (1998) 1.54
Antimicrobial resistance in the subgingival microflora in patients with adult periodontitis. A comparison between The Netherlands and Spain. J Clin Periodontol (2000) 1.52
Evidence of genetic heterogeneity in IBD: 1. The interleukin-1 receptor antagonist in the predisposition to suffer from ulcerative colitis. Eur J Gastroenterol Hepatol (1996) 1.52
Phase variation in Helicobacter pylori lipopolysaccharide due to changes in the lengths of poly(C) tracts in alpha3-fucosyltransferase genes. Infect Immun (1999) 1.51
Antibiotic-induced release of lipoteichoic acid and peptidoglycan from Staphylococcus aureus: quantitative measurements and biological reactivities. Antimicrob Agents Chemother (1998) 1.50
Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: diagnostic implications. Gut (1991) 1.50
Rapid quantitative assessment of gastric corpus atrophy in tissue sections. J Clin Pathol (2001) 1.50
Cloning and characterization of an accessory gene regulator (agr)-like locus from Staphylococcus epidermidis. FEMS Microbiol Lett (1998) 1.48
Insertion of mini-IS605 and deletion of adjacent sequences in the nitroreductase (rdxA) gene cause metronidazole resistance in Helicobacter pylori NCTC11637. Antimicrob Agents Chemother (1999) 1.48
In defense of Farr and Nightingale. Ann Intern Med (1996) 1.46
Identification of loci essential for the growth of Helicobacter pylori under acidic conditions. J Infect Dis (2000) 1.45
Relationship of bacterial growth phase to killing of Listeria monocytogenes by oxidative agents generated by neutrophils and enzyme systems. Infect Immun (1987) 1.44
The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl (2001) 1.43
Helicobacter pylori ribBA-mediated riboflavin production is involved in iron acquisition. J Bacteriol (1998) 1.42
[Whipple's disease]. Ned Tijdschr Geneeskd (1999) 1.41
Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion. Gastroenterology (1999) 1.40
[Enterobacter cloacae epidemic on a neonatal intensive care unit due to the use of contaminated thermometers]. Ned Tijdschr Geneeskd (2001) 1.39
Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol (1995) 1.39
Reliable gastric tonometry after coronary artery surgery: need for acid secretion suppression despite transient failure of acid secretion. Intensive Care Med (1998) 1.38
Percutaneous endoscopic gastrostomy: complications and suggestions to avoid them. Eur J Gastroenterol Hepatol (2001) 1.37
Third degree obstetric perineal tears: risk factors and the preventive role of mediolateral episiotomy. Br J Obstet Gynaecol (1997) 1.35
Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin Exp Immunol (1996) 1.33
Importance of the fiberoptic endoscope cleaning procedure for detection of Helicobacter pylori in gastric biopsy specimens by PCR. J Clin Microbiol (1994) 1.32
Why Helicobacter pylori has Lewis antigens. Trends Microbiol (2000) 1.32
Nosocomial outbreak of multi-resistant Acinetobacter baumannii on a surgical ward: epidemiology and risk factors for acquisition. J Hosp Infect (1997) 1.31
Neutrophil-activating protein mediates adhesion of Helicobacter pylori to sulfated carbohydrates on high-molecular-weight salivary mucin. Infect Immun (1998) 1.30
Treatment of reflux oesophagitis with ranitidine. Gut (1983) 1.29
Dendritic cells and scavenger macrophages in chronic inflammatory bowel disease. Gut (1989) 1.29
Veiled cells in chronic idiopathic inflammatory bowel disease. Clin Exp Immunol (1984) 1.29
The gastric H+,K+-ATPase is a major autoantigen in chronic Helicobacter pylori gastritis with body mucosa atrophy. Gastroenterology (1998) 1.26
HLA-DRB1*03, but not the TNFA -308 promoter gene polymorphism, confers protection against fistulising Crohn's disease. Immunogenetics (1998) 1.25
Esophagopleural fistula treated endoscopically with argon beam electrocoagulation and clips. Gastrointest Endosc (1999) 1.24
Identification of virulence genes of Helicobacter pylori by random insertion mutagenesis. Infect Immun (1999) 1.23
Helicobacter pylori-associated gastritis in mice is host and strain specific. Infect Immun (1999) 1.21
Large mononuclear Ia-positive veiled cells in Peyer's patches. I. Isolation and characterization in rat, guinea-pig and pig. Immunology (1983) 1.20
Large mononuclear Ia-positive veiled cells in Peyer's patches. II. Localization in rat Peyer's patches. Immunology (1983) 1.20
Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology (1990) 1.19
Outbreak of Bacillus cereus infections in a neonatal intensive care unit traced to balloons used in manual ventilation. J Clin Microbiol (2000) 1.19
Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut (1999) 1.18
Neutrophil cytoplasmic antibodies (p-ANCA) in ulcerative colitis. J Clin Pathol (1994) 1.17